Relay Therapeutics, Inc.

Relay Therapeutics, Inc.verified

RLAY

Price:

$9.23

Market Cap:

$1.23B

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology re...[Read more]

Industry

Biotechnology

IPO Date

2020-07-16

Stock Exchange

NASDAQ

Ticker

RLAY

The PE Ratio as of July 2024 (TTM) for Relay Therapeutics, Inc. (RLAY) is -3.26

According to Relay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.26. This represents a change of -13.37% compared to the average of -3.76 of the last 4 quarters.

Relay Therapeutics, Inc. (RLAY) Historical PE Ratio (quarterly & annually)

How has RLAY PE Ratio performed in the past?

The mean historical PE Ratio of Relay Therapeutics, Inc. over the last ten years is -9.43. The current -3.26 PE Ratio has changed 3.36% with respect to the historical average. Over the past ten years (40 quarters), RLAY's PE Ratio was at its highest in in the December 2020 quarter at 26.48. The PE Ratio was at its lowest in in the September 2020 quarter at -21.03.

Quarterly (TTM)
Annual

Average

-9.43

Median

-4.91

Minimum

-36.14

Maximum

-1.79

Relay Therapeutics, Inc. (RLAY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Relay Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.50%

Maximum Annual PE Ratio = -1.79

Minimum Annual Increase = -83.73%

Minimum Annual PE Ratio = -36.14

Quarterly (TTM)
Annual
YearPE RatioChange
2023-3.95-40.16%
2022-6.5912.14%
2021-5.88-83.73%
2020-36.141.50%
2019-2.2626.37%

Relay Therapeutics, Inc. (RLAY) Average PE Ratio

How has RLAY PE Ratio performed in the past?

The current PE Ratio of Relay Therapeutics, Inc. (RLAY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-5.47

5-year avg

-10.96

10-year avg

-9.43

Relay Therapeutics, Inc. (RLAY) PE Ratio vs. Peers

How is RLAY’s PE Ratio compared to its peers?

Relay Therapeutics, Inc.’s PE Ratio is greater than Stoke Therapeutics, Inc. (-6.15), greater than Pliant Therapeutics, Inc. (-4.58), greater than Black Diamond Therapeutics, Inc. (-3.98), greater than Arvinas, Inc. (-5.95), greater than Day One Biopharmaceuticals, Inc. (-6.46), greater than Mirati Therapeutics, Inc. (-5.32), less than Amylyx Pharmaceuticals, Inc. (-1.85), greater than Terns Pharmaceuticals, Inc. (-6.89), greater than Apellis Pharmaceuticals, Inc. (-11.16), less than Theseus Pharmaceuticals, Inc. (-3.19), less than aTyr Pharma, Inc. (-2.33), less than Century Therapeutics, Inc. (-1.16), greater than Blueprint Medicines Corporation (-24.96), greater than C4 Therapeutics, Inc. (-3.28), less than Monte Rosa Therapeutics, Inc. (-2.01), greater than Nurix Therapeutics, Inc. (-8.21), less than Foghorn Therapeutics Inc. (-2.98), greater than Edgewise Therapeutics, Inc. (-17.60), greater than Mineralys Therapeutics, Inc. (-6.82), greater than Cullinan Oncology, Inc. (-6.67),

Build a custom stock screener for Relay Therapeutics, Inc. (RLAY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relay Therapeutics, Inc. (RLAY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Relay Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Relay Therapeutics, Inc. (RLAY)?

What is the highest PE Ratio for Relay Therapeutics, Inc. (RLAY)?

What is the 3-year average PE Ratio for Relay Therapeutics, Inc. (RLAY)?

What is the 5-year average PE Ratio for Relay Therapeutics, Inc. (RLAY)?

How does the current PE Ratio for Relay Therapeutics, Inc. (RLAY) compare to its historical average?